Bull
$267.26
Scenario price
$365.080
0.000 (0.00%)At close
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Bio-Rad Laboratories Inc is a good buy right now due to its strong recent performance, with a 20-day change of +18.01% and a current price of 365.08, which is significantly above its 200-day simple moving average of 299.542. Additionally, the stock has a high RSI of 99.938, indicating strong momentum. However, the main risk is the negative earnings per share (EPS) of -19.55 reported in Q1 2026, which could impact investor sentiment.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

NYSE Suspends Trading of Bio-Rad Labs B; Additional Information Listed at $277.00

S&P 500 Futures Decline in Pre-Market Trading; Pinterest and Bio-Rad Labs Underperform

3 Stocks Signaling 'Buy' Opportunities for Investors Based on Technical Analysis

Bio-Rad Laboratories Reports Increase in Q3 Non-GAAP Earnings and Revenue

BIO Surpasses Average Analyst Expectations
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories. It operates in the Healthcare sector.
Bio-Rad Laboratories Inc is a good buy right now due to its strong recent performance, with a 20-day change of +18.01% and a current price of 365.08, which is significantly above its 200-day simple moving average of 299.542. Additionally, the stock has a high RSI of 99.938, indicating strong momentum. However, the main risk is the negative earnings per share (EPS) of -19.55 reported in Q1 2026, which could impact investor sentiment.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.